Imaging spontaneous MMTVneu transgenic murine mammary tumors: Targeting metabolic activity versus genetic products

Journal of Nuclear Medicine

Volumn 51, Issue 1, 2010, Pages 106-111

  Thakur, Mathew L ^a   Devadhas, Devakumar ^a   Zhang, Kaijun ^a   Pestell, Richard G ^a   Wang, Chenguang ^a   McCue, Peter ^b   Wickstrom, Eric ^a,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

64Cu TP3805; Oncogenic PET; Oncogenic vs. Metabolic imaging; PET of breast cancer; Transgenic MMTVneu mouse model

Indexed keywords

BIOLOGICAL MARKER; COPPER 64; CYCLIN D1; FLUORODEOXYGLUCOSE F 18; GENE PRODUCT; PEPTIDE DERIVATIVE; TP 3805; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST TUMOR; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; EARLY DIAGNOSIS; GOLD STANDARD; HISTOPATHOLOGY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; TRANSGENIC MOUSE;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLUORODEOXYGLUCOSE F18; HALF-LIFE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; ORGANOMETALLIC COMPOUNDS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; POSITRON-EMISSION TOMOGRAPHY; QUALITY CONTROL; RADIOPHARMACEUTICALS; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 75149180971     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.069542     Document Type: Article

References (24)

1. Tse GM, Yang W. Sonographic, mammographic, and histopathologic correlation of symptomatic ductal carcinoma in situ. AJR. 2004;182:101-110.
2. Uematsu T, Sano M, Homma K. False-positive helical CT findings of multifocal and multicentric breast cancer: is attenuation of tumor useful for diagnosing enhanced lesions? Breast Cancer. 2002;9:62-68.
3. Schnall M, Orel S. Breast MR imaging in the diagnostic setting. Magn Reson Imaging Clin N Am. 2006;14:329-337.
4. Ghai S, Muradali D, Bukhanov K, et al. Nonehancing breast malignancies on MRI: sonographic and pathologic correlation. AJR. 2005;185:481-487.
5. Smith AP, Hall PA, Marcello DM. Emerging technologies in breast cancer detection. Radiol Manage. 2004;26:16-24.
6. Elmore JG, Armstrong K, Lehman CD, et al. Screening for breast cancer. JAMA. 2005;293:1245-1256.
7. Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233:830-849.
8. Chagpar A, Middleton L, Sahin AA, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006;243:257-264.
9. Bombardiere E, Crippa F, Baio SM, et al. Nuclear medicine advances in breast cancer imaging. Tumori. 2003;87:277-287.
10. 18FDG-PET in patients with situ breast carcinomas: a cause of false negative results [in Spanish]. Med Clin (Barc). 2008;130:332-333.
11. Elter M, Shulz-Wendtland R, Wittenberg J. The prediction of breast cancer biopsy outcomes using two CAD approaches that both emphasize an intelligible decision process. Med Phys. 2007;34:4164-4172.
12. Zhang K, Aruva M, Shanthly N, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer; In vitro/in vivo evaluation. Regul Pept. 2007;144:91-100.
13. Thakur ML. Genomic biomarkers for molecular imaging: predicting the future. Semin Nucl Med. 2009;39:236-246.
14. Reubi JC, Laderach U, Waser B, et al. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 2000;60:3105-3112.
15. Zia H, Hida T, Jakowlew S, et al. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res. 1996;56:3486-3489.
16. Leyton J, Gozes Y, Zia F, et al. PACAP (6-38) is a PACAP receptor antagonist for breast cancer cells. Breast Cancer Res Treat. 1999;56:177-186.
17. Muller WJ, Arteaga CL, Muthuswamy SK, et al. Synergistic interaction of the neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol. 1996;16:5726-5736.
18. Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/β-catenin signaling. Cancer Res. 2006;66:8529-8541.
19. Pallela VR, Thakur ML, Chakder S, et al. Tc-99m labeled vasoactive intestinal peptide receptor agonist: functional studies. J Nucl Med. 1999;40:352-360.
20. -cells: possible role of VIP as a growth-promoting factor for hematopoietic stem/progenitor cells. Leukemia. 2004;18:912-921.
21. Reubi JC. In vitro identification of VIP receptors in human tumors: potential clinical implications. Ann NY Acad Sci. 1996;805:753-759.
22. Isasi CR, Moadel RM, Blaufox DM. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90:105-112.
23. Dose-Schwarz J, Mahner S, Schirrmacher S, et al. Detection of metastases in breast cancer patients: comparison of FDG PET with chest x-ray, bone scintigraphy and ultrasound of the abdomen. Nuklearmedizin. 2008;47:97-103.
24. Thakur ML, Aruva M, Garippa R, et al. PET imaging of oncogene overexpression using Cu-64-VIP analog: comparison with Tc-99m-VIP analog. J Nucl Med. 2004;45:1381-1389.